Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
boston blog main
boston top stories
8
×
europe blog main
8
×
europe top stories
fda
8
×
life sciences
national
8
×
national blog main
national top stories
new york blog main
new york top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alzheimer's disease
cancer immunotherapy
clinical trials
startups
cancer
deals
gilead sciences
investing
merck
philadelphia blog main
What
bio
roundup
cancer
days
amid
bombast
caught
companies
coronavirus
debate
develop
discussion
efforts
fda
ipo
life
market
meso’s
miss
new
pandemic
pfizer’s
presidential
promise
response
science
street
tuesday’s
vaccine
viewers
wall
week
abbvie’s
activity
ahead
alliance
approvals
arrival
biofourmis
biogen
Language
unset
8
×
Current search:
fda
×
biotech
×
" europe blog main "
×
unset
×
national
×
" boston top stories "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More